Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. develops and manages licensed healthcare assets while advancing a pipeline of novel, multifunctional biotherapeutics for oncology. Company news centers on Ziihera (zanidatamab-hrii) and zanidatamab-related regulatory and clinical updates, including HER2-targeted development, as well as ZW191, a folate receptor alpha-targeting antibody-drug conjugate with Fast Track designation for advanced or metastatic platinum-resistant ovarian cancer.
Recurring updates also cover antibody-drug conjugate platform work, including RAS inhibitor ADC programs and targets such as CLDN18.2, Ly6E and PTK7, along with financial results, cash resources, share repurchase activity, investor conference participation and executive leadership appointments.
Zymeworks (Nasdaq: ZYME) announced the U.S. FDA granted Fast Track designation to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for advanced or metastatic platinum‑resistant ovarian cancer (PROC) on March 30, 2026.
ZW191 is in an ongoing Phase 1 study (NCT06555744) evaluating safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity; FRα is reported in ~75% of high‑grade serous ovarian carcinomas, >50% of endometrial cancers, and ~70% of lung adenocarcinomas.
Zymeworks (Nasdaq: ZYME) announced management will participate in two investor conferences in April 2026: Needham 25th Annual Virtual Healthcare Conference and Bloom Burton & Co. Healthcare Investor Conference.
Presentations: April 15, 2026 at 10:15 AM ET (virtual) and April 21, 2026 in Toronto, ON. According to the company, management will hold one-on-one meetings and investor presentations at both events.
Zymeworks (Nasdaq: ZYME) announced four presentations at the AACR Annual Meeting (April 17-22, 2026) featuring data on Ziihera (zanidatamab-hrii), presented by partner Jazz Pharmaceuticals. Highlights include NeoZanHER Phase 2 neoadjuvant results with a statistically significant tumor-size reduction at six weeks and 30% pCR (n=6).
Additional abstracts cover mechanistic multi-omics of differentiated HER2 biology, activity after T-DXd, tumor-agnostic Phase 2 data, and adaptive biomarker-driven organ-preservation strategies in gastroesophageal adenocarcinoma.
Zymeworks (Nasdaq: ZYME) will present clinical and preclinical data at the AACR Annual Meeting April 17–22, 2026, including an oral presentation on April 21 reporting Part 1 results from the Phase 1 ZW191 dose‑escalation study.
Multiple posters (April 20–21) describe a novel pan‑RAS inhibitor ADC platform and preclinical candidates (ZW418, ZW427, ZW439, ZW437) showing potent activity and encouraging tolerability in RAS‑mutant cancer models.
Zymeworks (NASDAQ: ZYME) entered a $250 million non-recourse, royalty-backed note financing with Royalty Pharma on March 2, 2026. Repayments come from 30% of worldwide tiered royalties on Ziihera until repaid; Zymeworks retains 70% of royalties during repayment.
Royalty Pharma stops receiving payments after cumulative receipts of 1.65x the note by December 31, 2033 or 1.925x thereafter. Proceeds are non-dilutive, support share repurchases, potential strategic acquisitions, and extend cash runway beyond 2028. Zymeworks keeps up to $1.5 billion in remaining milestone payments tied to Ziihera.
Zymeworks (Nasdaq: ZYME) reported 2025 revenue of $106.0M (up 39% YoY) and a reduced net loss of $81.1M (down 34% YoY). Cash and marketable securities were $270.6M at year-end. The company closed a $250M non‑recourse royalty‑backed note and used $62.5M for share repurchases to March 2, 2026. Ziihera received approvals in Canada and the UK for biliary tract cancer, Jazz plans a potential U.S. GEA launch in 2H 2026, and up to $440M in GEA milestones are eligible.
Zymeworks (Nasdaq: ZYME) will report fourth quarter and full year 2025 financial results pre-market on March 2, 2026. Management will host a conference call and webcast the same day at 8:30 am Eastern Time to discuss results and provide a corporate update.
Zymeworks (Nasdaq: ZYME) said its management team will participate in several investor conferences in Feb–Mar 2026, including virtual and in-person events. Key engagements include one-on-one meetings at Citi’s 2026 Virtual Oncology Leadership Summit on Feb 18–19, 2026 (virtual); a one-on-one and a fireside chat at the TD Cowen 46th Annual Health Care Conference on Mar 2, 2026 at 14:30–15:00 ET in Boston; a one-on-one and fireside chat at the Leerink Annual Global Healthcare Conference on Mar 9, 2026 at 15:00 ET in Miami; and participation in the Citizens Life Science Conference on Mar 11, 2026 at 10:10 ET in Miami.
Zymeworks (Nasdaq: ZYME) announced board and leadership changes effective January 12, 2026 and early 2026 to align with its updated corporate strategy. Brian Cherry was appointed to the Board, bringing private equity and M&A experience. Mark Hollywood is promoted to Executive Vice President and Chief Operating Officer with expanded responsibilities. Dr. Sabeen Mekan will become Senior Vice President and Chief Medical Officer on February 1, 2026; current CMO Dr. Jeff Smith will retire January 31, 2026 and serve as an adviser during transition. The company initiated a search for a permanent CFO after departures in Q1 2026; Kenneth Galbraith is Acting CFO.
Zymeworks (Nasdaq: ZYME) outlined strategic priorities for 2026, highlighting positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2+ gastroesophageal adenocarcinoma and a planned supplemental BLA submission in 1H-2026. Key financials: potential regulatory milestones of $440.0M (US $250M, EU $100M, Japan $75M, China $15M), cash and marketable securities of approximately $270.6M as of Dec 31, 2025, and a $125.0M authorized share repurchase program (≈$19.0M used to date). Guidance includes ~$300.0M of adjusted gross operating expense (non-GAAP) over 2026–2028 and an expectation that cash plus anticipated milestones could fund operations beyond 2028.